Tag Archives: Myriad Genetics

December, 2018

20 December
FDA Approves Myriad’s BRACAnalysis CDx as Companion Diagnostic for Lynparza in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer

SALT LAKE CITY, Dec. 19, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with advanced ovarian cancer who have a germline BRCAmutation …
Share
7 December
Myriad Study Demonstrates EndoPredict Can Guide Chemotherapy Decision for Women with Early-Stage Breast Cancer

SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that academic researchers from the Technical University of Munich (TUM) presented the first prospective outcomes data on EndoPredict® at the San Antonio Breast Cancer Symposium in San Antonio, Texas. …
Share

27 September
Myriad Announces New GeneSight Study Published in Personalized Medicine

SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that a health economic study to evaluate the financial impact of the GeneSight® combinatorial pharmacogenomic (CPGx) test on major commercial health plans was published in the journal Personalized Medicine. The …
Share

3 January
Myriad and AstraZeneca Partner on Phase 3 PARP Inhibitor Trial Utilizing myChoice HRD Plus as a Companion Diagnostic

SALT LAKE CITY, Jan. 03, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza …
Share

22 February
Myriad Expands Diagnostic Research Collaboration with TESARO and Merck

SALT LAKE CITY, Feb. 22, 2016 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a strategic research collaboration with TESARO and Merck, known as MSD outside the U.S. and Canada, to help identify potential responders to an investigational combination drug therapy …
Share

1 April
Myriad and AstraZeneca Expand Companion Diagnostic Collaboration into Lynparza Study in Pancreatic Cancer Patients

Myriad Genetics, Inc. and AstraZeneca have expanded their companion diagnostic collaboration to include the utilization of Myriad’s diagnostic test to identify best responders to AstraZeneca’s investigational pancreatic cancer drug. The companies said that under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx test will be used prospectively to identify …
Share

19 March
Myriad Expands Collaboration with BioMarin for Cancer Companion Diagnostic Test

Myriad Genetics recently announced that it has expanded its collaboration with BioMarin Pharmaceutical to use Myriad’s myChoice HRD companion diagnostic test. Under the deal, BioMarin will use Myriad’s myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive …
Share